Company Description
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China.
It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer.
Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers.
It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products.
The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.
Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
| Country | China |
| Founded | 2014 |
| IPO Date | Jun 12, 2020 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 674 |
| CEO | Yusheng Han |
Contact Details
Address: No. 5, Xingdao Ring Road North, International Bio Island Guangzhou, 510005 China | |
| Phone | 86 20 3403 7871 |
| Website | brbiotech.com |
Stock Details
| Ticker Symbol | BNR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| IPO Price | $16.50 |
| CIK Code | 0001792267 |
| CUSIP Number | 12233L107 |
| ISIN Number | US12233L1070 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Yusheng Han | Founder, Chairman and Chief Executive Officer |
| Xiaozhi Hu | Senior Director of Finance |
| Dr. Zhihong Zhang | Chief Technology Officer and Director |
| Hao Liu | Senior Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 25, 2025 | 6-K | Report of foreign issuer |
| Dec 31, 2024 | 6-K | Report of foreign issuer |
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Dec 3, 2024 | 6-K | Report of foreign issuer |
| Nov 27, 2024 | UPLOAD | Filing |
| Nov 26, 2024 | 20-F/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | UPLOAD | Filing |
| Sep 27, 2024 | 6-K | Report of foreign issuer |